ASSESSING THE RISK FOR AUTOIMMUNE DISORDERS FOLLOWING USE OF THE QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE: THE ONTARIO GRADE 8 HPV VACCINE COHORT STUDY

ASSESSING THE RISK FOR AUTOIMMUNE DISORDERS FOLLOWING USE OF THE QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE: THE ONTARIO GRADE 8 HPV VACCINE COHORT STUDY

Introduction: In 2007 Ontario implemented a grade 8 quadrivalent human papillomavirus (qHPV) vaccination program targeting the virus that causes cervical cancer. Despite being 6 years post-implementation, few post-licensure studies have assessed the safety of the qHPV vaccine in this adolescent popu...

Full description

Bibliographic Details
Main Author:	Liu, Yiran
Other Authors:	Queen's University (Kingston, Ont.). Theses (Queen's University (Kingston, Ont.))
Language:	en en
Published:	2014
Subjects:	HPV Epidemiology Observational study Quadrivalent human papillomavirus vaccine Self-controlled case series Vaccine safety
Online Access:	http://hdl.handle.net/1974/12071

Similar Items

The Risk of Serious Respiratory-Related Events Following Immunization with the Quadrivalent Human Papillomavirus (qHPV) Vaccine: The Ontario Grade 8 HPV Vaccine Cohort Study
by: CHEUNG, MELANIE T
Published: (2014)

The Use and Neurological Safety of the Quadrivalent Human Papillomavirus (HPV) Vaccine: The Ontario Grade 8 HPV Vaccine Cohort Study
by: Lim, Wen Ting
Published: (2012)

Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial)
by: Macey L. Murray, et al.
Published: (2018-11-01)

Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study
by: Ingrid Herta Rotstein Grein, et al.
Published: (2020-11-01)

Determinants of non-uptake of the quadrivalent HPV vaccine; The Ontario Grade 8 HPV Vaccine Cohort Study
by: Remes, OLIVIA
Published: (2013)

Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries
by: Susanne K. Kjaer, et al.
Published: (2020-06-01)

The averted costs due to influenza vaccination with trivalent and quadrivalent vaccines
by: S. M. Kharit, et al.
Published: (2017-06-01)

Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection
by: Ana Gradissimo, et al.
Published: (2021-08-01)

Investigation on Spontaneous Abortion and Human Papillomavirus Infection
by: Mauro Tognon, et al.
Published: (2020-08-01)

INFLUENZA VACCINATION OF CHILDREN OF PRESCHOOL AGE IN THE RUSSIAN FEDERATION: COST-EFFECTIVENESS OF QUADRIVALENT VACCINE
by: A. V. Rudakova, et al.
Published: (2019-03-01)

Post-hoc analysis of injection-site reactions following vaccination with quadrivalent human papillomavirus vaccine in Japanese female clinical trial participants
by: Shinya Murata, et al.
Published: (2020-12-01)

Immunogenicity of a Quadrivalent Human Papillomavirus Vaccine When Co-Administered with Tetanus-Reduced Diphtheria-Acellular Pertussis and Quadrivalent Meningococcal Conjugate Vaccines in Healthy Adolescents: Results from a Randomized, Observer-Blind, Controlled Trial
by: Yan Miao, et al.
Published: (2019-08-01)

Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an ontario cohort of grade 8 girls
by: Kwong Jeffrey C, et al.
Published: (2011-08-01)

PHARMACOECONOMIC EFFICIENCY OF QUADRIVALENT VACCINE TO PREVENT HPV-ASSOCIATED DISEASES
by: I. A. DYAKOV
Published: (2016-12-01)

REGIONAL VACCINATION PROGRAM FOR THE PREVENTION OF HPV-ASSOCIATED DISEASES IN THE KHMAO-YUGRA
by: L. D. Belotsercovtseva, et al.
Published: (2014-07-01)

Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan
by: Iacopo Baussano, et al.
Published: (2021-01-01)

Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT
by: Richard Gilson, et al.
Published: (2020-09-01)

Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy
by: Francesca Carozzi, et al.
Published: (2018-01-01)

Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England
by: Dominic Thorrington, et al.
Published: (2017-09-01)

Exploration of the effect of human papillomavirus (HPV) vaccination in a cohort of pregnant women in Montreal, 2010–2016
by: El Hadji Malick Sarr, et al.
Published: (2019-08-01)

Human papillomavirus vaccination: An important tool in cervical cancer elimination
by: Veena Pampapati, et al.
Published: (2020-01-01)

Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia
by: Aurélien Jamotte, et al.
Published: (2016-07-01)

Human Papillomavirus (HPV): unawareness of the causal role of HPV infection in cervical cancer, HPV vaccine availability, and HPV vaccine uptake among female schoolteachers in a Middle Eastern country
by: Juman Rezqalla, et al.
Published: (2021-05-01)

Adverse events following Quadrivalent HPV vaccination reported in Sao Paulo State, Brazil, in the first three years after introducing the vaccine for routine immunization (March 2014 to December 2016)
by: Alexandre Blikstad Mauro, et al.

Efficacy and impact of quadrivalent human papillomavirus vaccine in male : a systematic review
by: Chan, Sze-tao, et al.
Published: (2014)

A Novel Approach to Guide Health Promotion Planning for Preventive Human Papillomavirus (HPV) Vaccination Among Adolescent Girls in an Ontario Public Health Unit
by: Rambout, Lisa
Published: (2012)

A Novel Approach to Guide Health Promotion Planning for Preventive Human Papillomavirus (HPV) Vaccination Among Adolescent Girls in an Ontario Public Health Unit
by: Rambout, Lisa
Published: (2012)

A Novel Approach to Guide Health Promotion Planning for Preventive Human Papillomavirus (HPV) Vaccination Among Adolescent Girls in an Ontario Public Health Unit
by: Rambout, Lisa
Published: (2012)

Knowledge level and attitude for Human Papillomavirus (HPV) infection and HPV vaccines among medical school students
by: Ömer Tolga Güler, et al.
Published: (2020-09-01)

Defining Elimination of Genital Warts—A Modified Delphi Study
by: Laila Khawar, et al.
Published: (2020-06-01)

Assessment of the State of Knowledge about HPV Infection and HPV Vaccination among Polish Resident Doctors
by: Katarzyna Smolarczyk, et al.
Published: (2021-01-01)

Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults
by: Hoan Jong Lee, et al.
Published: (2014-11-01)

Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
by: Analia Urueña, et al.
Published: (2021-04-01)

Immunogenicity of 2-dose pre-exposure rabies vaccine co-administered with quadrivalent influenza vaccine in children
by: Napaporn Chantasrisawad, et al.
Published: (2021-11-01)

Cost-effectiveness analysis of quadrivalent vaccine for prevention of cervical cancer in Serbia
by: Stojić Isidora
Published: (2012-01-01)

Ten years of anti-HPV vaccinations: what do we know?
by: Robert Jach, et al.
Published: (2016-11-01)

Resolution of Novel Human Papillomavirus–induced Warts after HPV Vaccination
by: Steffi Silling, et al.
Published: (2014-01-01)

Costs per DALYs Averted of Quadrivalent Influenza Vaccine versus Trivalent Influenza Vaccine in Elderly Population in Thailand
by: Jadesada Lertsirimunkong, et al.
Published: (2021-03-01)

Assessment of Reactogenicity and Immunogenicity of the Quadrivalent Live Attenuated Influenza Vaccine
by: D. A. Lioznov, et al.
Published: (2018-06-01)

Quadrivalent HPV vaccine and the risk of type 1 diabetes mellitus in grade 8 girls: A population based cohort study
by: Walsh, Erica
Published: (2012)